Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol
2026年5月5日 更新者：Celltrion Pharm, Inc.
A Multi-center, Randomized, Double-blind, Active-controlled, Phase III Trial to Evaluate the Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia
The goal of this clinical trial is to test whether one pill that combines ezetimibe, rosuvastatin, and amlodipine can safely lower cholesterol and blood pressure in Korean adults with high blood pressure and high cholesterol.
調査の概要
状態
完了
条件
詳細な説明
Amlodipine is a calcium channel blocker used for the treatment of hypertension. Rosuvastatin is a statin that inhibits HMG-CoA reductase and is widely used for the treatment of hypercholesterolemia. Ezetimibe is a lipid-lowering agent that inhibits intestinal cholesterol absorption and is commonly used in combination with statins.
This multicenter, randomized, double-blind, active-controlled, phase 3 clinical trial evaluates the efficacy and safety of a fixed-dose combination of ezetimibe, rosuvastatin, and amlodipine in Korean adults with essential hypertension and primary hypercholesterolemia. Following a run-in period that includes therapeutic lifestyle modification, participants are randomized in a 1:1:1 ratio to receive ezetimibe/rosuvastatin/amlodipine 10/20/10 mg or amlodipine 10 mg, or ezetimibe/rosuvastatin 10/20 mg for 8 weeks.
A total of 163 participants were enrolled across 21 study sites. Low-density lipoprotein cholesterol (LDL-C) levels and mean sitting systolic blood pressure (MSSBP) are assessed at Weeks 4 and 8. The primary efficacy endpoints are the percent change in LDL-C from baseline at Week 8 and the change in MSSBP from baseline at Week 8. Secondary endpoints include changes in total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides, non-HDL-C, and apolipoprotein B (ApoB).
研究の種類
介入
入学 (実際)
163
段階
- フェーズ 3
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
-
Ansan、韓国
- Korea University Ansan Hospital
-
Anyang、韓国
- Hallym University Sacred Heart Hospital
-
Busan、韓国
- Kosin University Gospel Hospital
-
Busan、韓国
- Pusan National University Hospital
-
Cheonan、韓国
- Dankook University Hospital
-
Daegu、韓国
- Keimyung University Dongsan Medical Center
-
Daegu、韓国
- Yeungnam University Hospital
-
Daegu、韓国
- Daegu Catholic University Medical Center
-
Gwangju、韓国
- Chonnam National University Hospital
-
Incheon、韓国
- Gachon University Gil Medical Center
-
Jeonju、韓国
- Jeonbuk National University Hospital
-
Seongnam、韓国
- CHA University Bundang Medical Center
-
Seoul、韓国
- Asan Medical Center
-
Seoul、韓国
- Kangbuk Samsung Hospital
-
Seoul、韓国
- Korea University Anam Hospital
-
Seoul、韓国
- Korea University Guro Hospital
-
Seoul、韓国
- Severance Hospital
-
Seoul、韓国
- The Catholic University of Korea Seoul St. Mary's Hospital
-
Seoul、韓国
- Nowon Eulji Medical Center, Eulji University
-
Uijeongbu-si、韓国
- Uijeongbu Eulji Medical Center, Eulji University
-
Uijeongbu-si、韓国
- The Catholic University of Korea Uijeongbu St. Mary's Hospital
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
説明
Screening Inclusion Criteria:
- Age 19 years or older at the time of written informed consent
- Diagnosed with essential hypertension and primary hypercholesterolemia, or currently receiving antihypertensive and/or lipid-lowering medication after such diagnosis
- If receiving antihypertensive and/or lipid-lowering therapy at screening, judged by the investigator to be medically appropriate for discontinuation of prior therapy during the clinical trial period
- Able and willing to voluntarily sign the written informed consent form after receiving an explanation of the purpose, methods, and expected effects of the study
Randomization Inclusion Criteria:
- Mean sitting systolic blood pressure (MSSBP) of at least 140 mmHg and less than 180 mmHg, and mean sitting diastolic blood pressure (MSDBP) less than 110 mmHg
- Completion of at least 4 weeks of therapeutic lifestyle modification before administration of the investigational product
- After at least 4 weeks of therapeutic lifestyle modification, fasting LDL-C meeting one of the following criteria:
- Very high-risk group: LDL-C 70 mg/dL or higher in participants with coronary artery disease, atherosclerotic ischemic stroke or transient ischemic attack, or peripheral arterial disease
- High-risk group: LDL-C 100 mg/dL or higher in participants with carotid artery disease, abdominal aneurysm, or diabetes mellitus
- Moderate-risk group: LDL-C 130 mg/dL or higher in participants with 2 or more major risk factors
- Low-risk group: LDL-C 160 mg/dL or higher in participants with 1 or fewer major risk factors
- Fasting triglycerides less than 400 mg/dL and LDL-C 250 mg/dL or lower
Exclusion Criteria:
- MSSBP ≥ 180 mmHg or MSDBP ≥ 110 mmHg at screening or randomization
- Difference between arms at screening of MSSBP ≥ 20 mmHg and MSDBP ≥ 10 mmHg
- History of secondary hypertension or medical history suggestive of secondary hypertension, including coarctation of the aorta, hyperaldosteronism, renal artery stenosis, Cushing disease, pheochromocytoma, or polycystic kidney disease, etc.
- Symptomatic orthostatic hypotension, defined as a decrease in systolic blood pressure of 20 mmHg or more or diastolic blood pressure of 10 mmHg or more on standing compared with sitting or supine blood pressure
- Subjects with secondary dyslipidemia
- Severe cardiac disease, including congestive heart failure (NYHA class III or IV), clinically significant arrhythmia, hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, or hemodynamically significant stenosis of the aortic or mitral valve
- Unstable angina, myocardial infarction, transient ischemic attack, cerebrovascular disease, coronary artery bypass grafting, or percutaneous coronary intervention within 6 months prior to screening
- Retinal hemorrhage, including visual impairment, within 6 months prior to screening
- Chronic inflammatory disease requiring treatment (e.g., rheumatoid arthritis), or wasting disease, autoimmune disease, or connective tissue disease
- Endocrine or metabolic disease known to affect serum lipids or lipoproteins, including uncontrolled diabetes mellitus (HbA1c > 9%) or uncontrolled thyroid dysfunction (TSH > 1.5 times the upper limit of normal)
- Severe renal or hepatic impairment, defined as AST or ALT > 3 times the upper limit of normal, or serum creatinine > 1.5 times the upper limit of normal
- History of myopathy or rhabdomyolysis, or creatine kinase (CK) > 2 times the upper limit of normal
- Patients who received, before study participation, treatment with medications that may affect lipid levels, including bile acid sequestrants, anti-obesity medications, fibrates, niacin, or systemic steroid therapy; however, participation is permitted if the relevant washout period has been completed.
- Need for treatment with protocol-prohibited concomitant medications during the study period
- History of hypersensitivity to ezetimibe, rosuvastatin, amlodipine, or related drug classes
- Patients with gastrointestinal disease or a history of surgery that may affect drug absorption, distribution, metabolism, or excretion, including current active gastritis, gastrointestinal or rectal bleeding, a history of major gastrointestinal surgery, a history of active inflammatory bowel disease within 12 months before screening, or hereditary disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
- History of drug or alcohol abuse
- Pregnant or breastfeeding participants, or participants unwilling to use appropriate contraception during the study period
- History of malignancy within 5 years before screening, except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, thyroid cancer, or carcinoma in situ of other sites, provided that the disease was successfully treated and there has been no recurrence for at least 3 years; enrollment may be considered at the investigator's medical discretion.
- Use of another investigational product within 4 weeks prior to screening
- Any other condition or circumstance that, in the investigator's judgment, would make the participant unsuitable for study participation
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Amlodipine, Ezetimibe/Rosuvastatin
|
Oral tablet containing amlodipine 10 mg administered for 8 weeks.
Fixed-dose combination oral tablet containing ezetimibe 10 mg and rosuvastatin 20 mg administered for 8 weeks.
|
|
アクティブコンパレータ：Amlodipine, Ezetimibe/Rosuvastatin placebo
|
Oral tablet containing amlodipine 10 mg administered for 8 weeks.
Placebo for ezetimibe/rosuvastatin (10mg/20mg)
|
|
アクティブコンパレータ：Amlodipine placebo, Ezetimibe/Rosuvastatin
|
Fixed-dose combination oral tablet containing ezetimibe 10 mg and rosuvastatin 20 mg administered for 8 weeks.
Placebo for amlodipine (10mg)
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8 in Treatment Group and Control Group 1
時間枠：Baseline, Week 8
|
Percent change from baseline in LDL-C level.
|
Baseline, Week 8
|
|
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 in Treatment Group and Control Group 2
時間枠：Baseline, Week 8
|
Change from baseline in mean sitting systolic blood pressure.
Change is calculated as the Week 8 value minus the baseline value.
|
Baseline, Week 8
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 4 in the Treatment Group and Control Group 1
時間枠：Baseline, Week 4
|
Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 4 in the treatment group and control group 1.
|
Baseline, Week 4
|
|
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 4 in the Treatment Group and Control Group 2
時間枠：Baseline, Week 4
|
Change from baseline in mean sitting systolic blood pressure (MSSBP) at Week 4 in the treatment group and control group 2.
|
Baseline, Week 4
|
|
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Weeks 4 and 8 in the Treatment Group and Control Group 1
時間枠：Baseline, Week 4, Week 8
|
Change from baseline in mean sitting systolic blood pressure (MSSBP) at Weeks 4 and 8 in the treatment group and control group 1.
|
Baseline, Week 4, Week 8
|
|
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 4 and 8 in the Treatment Group and Control Group 2
時間枠：Baseline, Week 4, Week 8
|
Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Weeks 4 and 8 in the treatment group and control group 2.
|
Baseline, Week 4, Week 8
|
|
Percent Change From Baseline in TC, TG, HDL-C, non-HDL-C, and Apo B at Weeks 4 and 8 in the Treatment Group, Control Group 1 and Control Group 2
時間枠：Baseline, Week 4, Week 8
|
Percent change from baseline in total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (Apo B) at Weeks 4 and 8 in the treatment group, control group 1, and control group 2.
|
Baseline, Week 4, Week 8
|
|
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Weeks 4 and 8 in the Treatment Group, Control Group 1, and Control Group 2
時間枠：Baseline, Week 4, Week 8
|
Change from baseline in mean sitting diastolic blood pressure (MSDBP) at Weeks 4 and 8 in the treatment group, control group 1, and control group 2.
|
Baseline, Week 4, Week 8
|
|
Proportion of Participants Achieving Target Blood Pressure at Weeks 4 and 8 in the Treatment Group, Control Group 1, and Control Group 2
時間枠：Week 4, Week 8
|
Proportion of participants who achieved target blood pressure at Weeks 4 and 8 in the treatment group, control group 1, and control group 2. Target blood pressure is defined as MSSBP/MSDBP <140/90 mmHg.
For participants with high-risk diabetes mellitus, chronic kidney disease with diabetes mellitus or albuminuria, concomitant cardiovascular disease, or high-risk hypertension, target blood pressure is defined as MSSBP/MSDBP <130/80 mmHg.
|
Week 4, Week 8
|
|
Proportion of Participants Achieving Target Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 4 and 8 in the Treatment Group, Control Group 1, and Control Group 2
時間枠：Week 4, Week 8
|
Proportion of participants who achieved target low-density lipoprotein cholesterol (LDL-C) at Weeks 4 and 8 in the treatment group, control group 1, and control group 2. Target LDL-C is defined according to cardiovascular risk category as follows: very high-risk, <70 mg/dL; high-risk, <100 mg/dL; moderate-risk, <130 mg/dL; and low-risk, <160 mg/dL.
|
Week 4, Week 8
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2022年8月5日
一次修了 (実際)
2024年2月13日
研究の完了 (実際)
2024年2月13日
試験登録日
最初に提出
2026年4月27日
QC基準を満たした最初の提出物
2026年4月27日
最初の投稿 (実際)
2026年5月4日
学習記録の更新
投稿された最後の更新 (実際)
2026年5月8日
QC基準を満たした最後の更新が送信されました
2026年5月5日
最終確認日
2026年5月1日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- CTP-EAR 3.1
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
いいえ
IPD プランの説明
This completed study is being registered retrospectively, and no prospective plan for IPD sharing was specified in the original protocol.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。